A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date

Imipenem-relebactam (I-R) is a novel beta-lactam/beta-lactamase inhibitor combination given with cilastatin. It is indicated for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired or ventilator-associated bacterial pneumonia. A litera...

Descripción completa

Detalles Bibliográficos
Autores principales: Campanella, Toni A, Gallagher, Jason C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701153/
https://www.ncbi.nlm.nih.gov/pubmed/33268997
http://dx.doi.org/10.2147/IDR.S224228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701153/
https://www.ncbi.nlm.nih.gov/pubmed/33268997
http://dx.doi.org/10.2147/IDR.S224228

Ejemplares similares